Routine Use Of Cinacalcet Therapy In People With Chronic Kidney Disease No Longer Recommended

Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and parathyroid blood levels within a target range has few patient level clinical benefits and several adverse effects, suggesting that it should no longer be routinely prescribed, according to a study by international researchers published in this week's PLOS Medicine. These findings are important as cinacalcet has become the largest single drug cost for patients on dialysis in the US, with an annual expenditure of at least US $260 million...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Urology / Nephrology Source Type: news